➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Medtronic
AstraZeneca
McKinsey
Baxter
Boehringer Ingelheim
Harvard Business School

Last Updated: September 27, 2021

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR FASIGLIFAM


Email this page to a colleague

« Back to Dashboard

Clinical Trials for Fasiglifam

Trial ID Title Status Sponsor Phase Summary
NCT01456195 ↗ Comparison of TAK-875 (Fasiglifam) With Placebo in Participants With Type 2 Diabetes Completed Takeda Phase 3 The purpose of this study is to determine the efficacy and safety of TAK-875 (fasiglifam), once daily (QD), in participants with type 2 diabetes mellitus (T2DM).
NCT01481116 ↗ Efficacy and Safety of TAK-875 Compared to Glimepiride When Used With Metformin in Participants With Type 2 Diabetes Terminated Takeda Phase 3 The purpose of this study is to determine the efficacy and safety of TAK-875, once daily (QD), plus metformin compared to glimepiride plus metformin in participants with type 2 diabetes mellitus (T2DM). The purpose of this study is to determine the efficacy and safety of TAK-875, once daily (QD), plus metformin compared to glimepiride plus metformin in participants with type 2 diabetes mellitus (T2DM).
NCT01549964 ↗ Comparison of Fasiglifam (TAK-875) to Placebo and Sitagliptin in Combination With Metformin in Participants With Type 2 Diabetes Terminated Takeda Phase 3 The purpose of this study is to evaluate the efficacy of 2 doses of TAK-875 (25 mg and 50 mg), once daily (QD), plus metformin compared to placebo plus metformin and sitagliptin plus metformin on lowering blood sugar.
NCT01609582 ↗ Study of TAK-875 in Adults With Type 2 Diabetes and Cardiovascular Disease or Risk Factors for Cardiovascular Disease Terminated Takeda Phase 3 The purpose of this study is to demonstrate no excess risk of cardiovascular (CV) composite events exists following long term treatment with TAK-875 compared with placebo.
NCT01647542 ↗ Study to Evaluate the Efficacy and Safety of Daily Oral TAK-875 25 and 50mg in Asia Pacific Adults With Type 2 Diabetes Terminated Takeda Phase 3 The purpose of this study is to evaluate the efficacy and safety of TAK-875 in Asia Pacific adults with type 2 diabetes mellitus (T2DM).
NCT01829464 ↗ TAK-875 (Fasiglifam) in Combination With Sitagliptin in Adults With Type 2 Diabetes Terminated Takeda Phase 3 The purpose of this study is to evaluate the effect of TAK-875 (fasiglifam) in combination with sitagliptin on glycemic control in adults with type 2 diabetes.
>Trial ID >Title >Status >Phase >Summary

Clinical Trial Conditions for Fasiglifam

Condition Name

Condition Name for
Intervention Trials
Diabetes Mellitus, Type 2 4
Type 2 Diabetes Mellitus 3
Chronic Kidney Disease 1
Cardiovascular Disease 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for
Intervention Trials
Diabetes Mellitus 9
Diabetes Mellitus, Type 2 8
Cardiovascular Diseases 1
Renal Insufficiency, Chronic 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Fasiglifam

Trials by Country

Trials by Country for
Location Trials
United States 205
United Kingdom 25
Argentina 21
Mexico 19
Malaysia 19
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for
Location Trials
Florida 9
Texas 9
South Carolina 9
Ohio 9
California 9
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Fasiglifam

Clinical Trial Phase

Clinical Trial Phase for
Clinical Trial Phase Trials
Phase 3 9
Phase 2 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for
Clinical Trial Phase Trials
Terminated 8
Withdrawn 1
Completed 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Fasiglifam

Sponsor Name

Sponsor Name for
Sponsor Trials
Takeda 10
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for
Sponsor Trials
Industry 10
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Johnson and Johnson
Harvard Business School
Express Scripts
AstraZeneca
McKinsey

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.